Tumor Cell-derived Exosomes-based Vaccines
Tumor Cell-derived Exosomes-based Vaccines represent an innovative approach in cancer immunotherapy, leveraging the natural properties of tumor-derived exosomes (TEXs) to present tumor-associated antigens (TAAs) and modulate immune responses. Exosomes secreted by tumor cells are nanoscale extracellular vesicles that encapsulate diverse molecular cargos, including proteins, lipids, and nucleic acids, reflecting the tumor's molecular signature. These vesicles naturally carry multiple TAAs, making them powerful tools for stimulating anti-tumor immunity without extensive antigen engineering. To translate these unique advantages into clinical applications, MtoZ Biolabs offers a comprehensive Tumor Cell-derived Exosomes-based Vaccines development service that supports the design, production, and characterization of exosome-based vaccines for cancer immunotherapy.
Unlike traditional cancer vaccines that often require synthetic antigen production or peptide modification, tumor-derived exosomes serve as intrinsic antigen carriers and immune modulators. They can activate dendritic cells (DCs), prime cytotoxic T lymphocytes (CTLs), and induce robust tumor-specific immune responses. Their biological compatibility, efficient delivery capacity, and low immunogenicity make them promising candidates for personalized cancer vaccines, especially in targeting heterogeneous and immune-evasive tumors. Despite these advantages, developing effective exosome-based vaccines requires overcoming several challenges, including the efficient isolation of highly pure and functional exosomes, precise characterization of exosomal cargo, and enhancement of their immunogenicity. Advanced strategies such as surface modification, antigen enrichment, and adjuvant integration are essential to optimize their therapeutic potential and safety profiles.
Figure 1. Tumor-derived Exosomes (TEXs) Carry and Deliver Both Immunosuppressive and Immunostimulatory Signals to Immune Cells in the Lung Tumor Microenvironment
Service at MtoZ Biolabs
MtoZ Biolabs offers a comprehensive Tumor Cell-derived Exosomes-based Vaccines development platform, integrating state-of-the-art exosome isolation, characterization, and engineering technologies. Our services include high-purity exosome isolation using ultracentrifugation, size exclusion chromatography (SEC), immunoaffinity capture, and microfluidic technologies, combined with in-depth cargo analysis through proteomics, RNA sequencing (including miRNA, lncRNA, and circRNA), and lipidomics. These services address key bottlenecks in exosome-based vaccine development, offering end-to-end solutions for translational research and preclinical development. By partnering with MtoZ Biolabs, researchers and biopharmaceutical companies can accelerate the discovery and development of exosome-based cancer vaccines. Free project evaluation, welcome to learn more details.
Service Advantages
☑️Advanced Technology Platform
Cutting-edge exosome isolation and characterization technologies, including ultracentrifugation, SEC, microfluidics, and multi-omics analysis, ensuring high-purity, functional exosomes for vaccine development.
☑️Comprehensive End-to-End Service
From tumor exosome isolation to vaccine optimization and functional validation, offering a seamless and customizable workflow aligned with research and therapeutic goals.
☑️Expert Team with Extensive Experience
Professional team specialized in exosome biology, tumor immunology, and therapeutic development, providing technical guidance and tailored solutions throughout the project lifecycle.
☑️Transparent Pricing with Cost-effective Models
Clear and transparent pricing structure with flexible service packages to meet the needs of academic research, translational medicine, and preclinical development.
Case Study
Tumor-Derived Exosomes Loaded with miR-124-3p as an Effective Cell-Free Cancer Vaccine
A recent study demonstrated that tumor cell-derived exosomes (TEXs) loaded with miR-124-3p (TEXomiR) can serve as effective cell-free cancer vaccines. Exosomes isolated from CT-26 colorectal cancer cells were engineered to carry miR-124-3p using a calcium chloride method. In vivo experiments showed that TEXomiR significantly inhibited tumor growth, prolonged survival, and enhanced cytotoxic T cell responses compared to controls. Notably, TEXomiR reduced immunosuppressive Treg/CD8 and CD4/CD8 ratios and promoted splenocyte proliferation and cytotoxicity. This study highlights the importance of developing Tumor Cell-derived Exosomes-based Vaccines as natural carriers that deliver both tumor antigens and therapeutic molecules, offering a promising strategy for personalized cancer immunotherapy.
Figure 2. In Vitro and In Vivo Assay for the Evaluation of Anti-Tumor Effects of miR-124-enriched Tumor Exosomes
FAQ
Q: What types of tumor cells are suitable for exosome vaccine development?
MtoZ Biolabs supports a wide range of tumor types, including but not limited to breast, lung, colorectal, glioblastoma, pancreatic, ovarian, prostate, melanoma, and hematological malignancies. Customization based on patient-derived tumor cells is also available for personalized vaccine solutions.
How to order?
